Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Ketty Peris; Niccolo' Gori; Maria Teresa Iannone; Maria Concetta Fargnoli; Katia Elisabetta Provenzano; Margherita Romanelli; C. Patruno; M. Napolitano; G. Argenziano; M. Ortoncelli; G. Girolomoni; S. M. Ferrucci; G. F. Amoruso; M. Rossi; L. Stingeni; G. Malara; C. Foti; M. Gattoni; C. Loi; M. Iannone; M. Talamonti; G. Stinco; P. D. Pigatto; A. Cristaudo; E. Nettis; M. Corazza; F. Guarneri; M. Esposito; A. Belloni Fortina; C. Potenza; G. Fabbrocini; L. Angileri; T. Bianchelli; A. Borghi; C. Buligan; G. Calabrese; P. Calzavara Pinton; F. Caroppo; C. Chello; G. Dal Bello; G. Damiani; M. C. Fargnoli; M. Ferrillo; M. Galluzzo; N. Gori; G. Gualdi; K. Hansel; L. Macchia; M. Mariano; S. P. Nisticò; G. Pertusi; V. Piras; E. Provenzano; G. M. Ravaioli; S. Ribero; M. Romanelli; P. Romita; E. Tolino; C. Trifirò

doi:10.1111/jdv.17094

Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Ketty Peris, Niccolo' Gori, Maria Teresa Iannone, Maria Concetta Fargnoli, Katia Elisabetta Provenzano, Margherita Romanelli, C. Patruno, M. Napolitano, G. Argenziano, M. Ortoncelli, G. Girolomoni, S. M. Ferrucci, G. F. Amoruso, M. Rossi, L. Stingeni, G. Malara, C. Foti, M. Gattoni, C. Loi, M. IannoneM. Talamonti, G. Stinco, P. D. Pigatto, A. Cristaudo, E. Nettis, M. Corazza, F. Guarneri, M. Esposito, A. Belloni Fortina, C. Potenza, G. Fabbrocini, L. Angileri, T. Bianchelli, A. Borghi, C. Buligan, G. Calabrese, P. Calzavara Pinton, F. Caroppo, C. Chello, G. Dal Bello, G. Damiani, M. C. Fargnoli, M. Ferrillo, M. Galluzzo, N. Gori, G. Gualdi, K. Hansel, L. Macchia, M. Mariano, S. P. Nisticò, G. Pertusi, V. Piras, E. Provenzano, G. M. Ravaioli, S. Ribero, M. Romanelli, P. Romita, E. Tolino, C. Trifirò

Research output: Contribution to journal › Article

5 Citations (Scopus)

Abstract

Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

Original language	English
Pages (from-to)	N/A-N/A
Journal	Journal of the European Academy of Dermatology and Venereology
DOIs	https://doi.org/10.1111/jdv.17094
Publication status	Published - 2020

Keywords

atopic dermatitis
dupilumab

Access to Document

10.1111/jdv.17094

Cite this

Peris, K., Gori, N., Iannone, M. T., Fargnoli, M. C., Provenzano, K. E., Romanelli, M., Patruno, C., Napolitano, M., Argenziano, G., Ortoncelli, M., Girolomoni, G., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Foti, C., Gattoni, M., Loi, C., ... Trifirò, C. (2020). Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. Journal of the European Academy of Dermatology and Venereology, N/A-N/A. https://doi.org/10.1111/jdv.17094

Peris, Ketty ; Gori, Niccolo' ; Iannone, Maria Teresa ; Fargnoli, Maria Concetta ; Provenzano, Katia Elisabetta ; Romanelli, Margherita ; Patruno, C. ; Napolitano, M. ; Argenziano, G. ; Ortoncelli, M. ; Girolomoni, G. ; Ferrucci, S. M. ; Amoruso, G. F. ; Rossi, M. ; Stingeni, L. ; Malara, G. ; Foti, C. ; Gattoni, M. ; Loi, C. ; Iannone, M. ; Talamonti, M. ; Stinco, G. ; Pigatto, P. D. ; Cristaudo, A. ; Nettis, E. ; Corazza, M. ; Guarneri, F. ; Esposito, M. ; Belloni Fortina, A. ; Potenza, C. ; Fabbrocini, G. ; Angileri, L. ; Bianchelli, T. ; Borghi, A. ; Buligan, C. ; Calabrese, G. ; Calzavara Pinton, P. ; Caroppo, F. ; Chello, C. ; Dal Bello, G. ; Damiani, G. ; Fargnoli, M. C. ; Ferrillo, M. ; Galluzzo, M. ; Gori, N. ; Gualdi, G. ; Hansel, K. ; Macchia, L. ; Mariano, M. ; Nisticò, S. P. ; Pertusi, G. ; Piras, V. ; Provenzano, E. ; Ravaioli, G. M. ; Ribero, S. ; Romanelli, M. ; Romita, P. ; Tolino, E. ; Trifirò, C. / Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. In: Journal of the European Academy of Dermatology and Venereology. 2020 ; pp. N/A-N/A.

@article{8d49d4e804b440f8af9cbf792d5aeb2c,

title = "Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study",

abstract = "Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.",

keywords = "atopic dermatitis, dupilumab, atopic dermatitis, dupilumab",

author = "Ketty Peris and Niccolo' Gori and Iannone, {Maria Teresa} and Fargnoli, {Maria Concetta} and Provenzano, {Katia Elisabetta} and Margherita Romanelli and C. Patruno and M. Napolitano and G. Argenziano and M. Ortoncelli and G. Girolomoni and Ferrucci, {S. M.} and Amoruso, {G. F.} and M. Rossi and L. Stingeni and G. Malara and C. Foti and M. Gattoni and C. Loi and M. Iannone and M. Talamonti and G. Stinco and Pigatto, {P. D.} and A. Cristaudo and E. Nettis and M. Corazza and F. Guarneri and M. Esposito and {Belloni Fortina}, A. and C. Potenza and G. Fabbrocini and L. Angileri and T. Bianchelli and A. Borghi and C. Buligan and G. Calabrese and {Calzavara Pinton}, P. and F. Caroppo and C. Chello and {Dal Bello}, G. and G. Damiani and Fargnoli, {M. C.} and M. Ferrillo and M. Galluzzo and N. Gori and G. Gualdi and K. Hansel and L. Macchia and M. Mariano and Nistic{\`o}, {S. P.} and G. Pertusi and V. Piras and E. Provenzano and Ravaioli, {G. M.} and S. Ribero and M. Romanelli and P. Romita and E. Tolino and C. Trifir{\`o}",

year = "2020",

doi = "10.1111/jdv.17094",

language = "English",

pages = "N/A--N/A",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Elsevier BV:PO Box 211, 1000 AE Amsterdam Netherlands:011 31 20 4853757, 011 31 20 4853642, 011 31 20 4853641, EMAIL: nlinfo-f@elsevier.nl, INTERNET: http://www.elsevier.nl, Fax: 011 31 20 4853598",

}

Peris, K , Gori, N, Iannone, MT, Fargnoli, MC, Provenzano, KE, Romanelli, M, Patruno, C, Napolitano, M, Argenziano, G, Ortoncelli, M, Girolomoni, G, Ferrucci, SM, Amoruso, GF, Rossi, M, Stingeni, L, Malara, G, Foti, C, Gattoni, M, Loi, C, Iannone, M, Talamonti, M, Stinco, G, Pigatto, PD, Cristaudo, A, Nettis, E, Corazza, M, Guarneri, F, Esposito, M, Belloni Fortina, A, Potenza, C, Fabbrocini, G, Angileri, L, Bianchelli, T, Borghi, A, Buligan, C, Calabrese, G, Calzavara Pinton, P, Caroppo, F, Chello, C, Dal Bello, G, Damiani, G, Fargnoli, MC, Ferrillo, M, Galluzzo, M, Gori, N, Gualdi, G, Hansel, K, Macchia, L, Mariano, M, Nisticò, SP, Pertusi, G, Piras, V, Provenzano, E, Ravaioli, GM, Ribero, S, Romanelli, M, Romita, P, Tolino, E & Trifirò, C 2020, 'Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study', Journal of the European Academy of Dermatology and Venereology, pp. N/A-N/A. https://doi.org/10.1111/jdv.17094

Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. / Peris, Ketty ; Gori, Niccolo'; Iannone, Maria Teresa; Fargnoli, Maria Concetta; Provenzano, Katia Elisabetta; Romanelli, Margherita; Patruno, C.; Napolitano, M.; Argenziano, G.; Ortoncelli, M.; Girolomoni, G.; Ferrucci, S. M.; Amoruso, G. F.; Rossi, M.; Stingeni, L.; Malara, G.; Foti, C.; Gattoni, M.; Loi, C.; Iannone, M.; Talamonti, M.; Stinco, G.; Pigatto, P. D.; Cristaudo, A.; Nettis, E.; Corazza, M.; Guarneri, F.; Esposito, M.; Belloni Fortina, A.; Potenza, C.; Fabbrocini, G.; Angileri, L.; Bianchelli, T.; Borghi, A.; Buligan, C.; Calabrese, G.; Calzavara Pinton, P.; Caroppo, F.; Chello, C.; Dal Bello, G.; Damiani, G.; Fargnoli, M. C.; Ferrillo, M.; Galluzzo, M.; Gori, N.; Gualdi, G.; Hansel, K.; Macchia, L.; Mariano, M.; Nisticò, S. P.; Pertusi, G.; Piras, V.; Provenzano, E.; Ravaioli, G. M.; Ribero, S.; Romanelli, M.; Romita, P.; Tolino, E.; Trifirò, C.

In: Journal of the European Academy of Dermatology and Venereology, 2020, p. N/A-N/A.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

AU - Peris, Ketty

AU - Gori, Niccolo'

AU - Iannone, Maria Teresa

AU - Fargnoli, Maria Concetta

AU - Provenzano, Katia Elisabetta

AU - Romanelli, Margherita

AU - Patruno, C.

AU - Napolitano, M.

AU - Argenziano, G.

AU - Ortoncelli, M.

AU - Girolomoni, G.

AU - Ferrucci, S. M.

AU - Amoruso, G. F.

AU - Rossi, M.

AU - Stingeni, L.

AU - Malara, G.

AU - Foti, C.

AU - Gattoni, M.

AU - Loi, C.

AU - Iannone, M.

AU - Talamonti, M.

AU - Stinco, G.

AU - Pigatto, P. D.

AU - Cristaudo, A.

AU - Nettis, E.

AU - Corazza, M.

AU - Guarneri, F.

AU - Esposito, M.

AU - Belloni Fortina, A.

AU - Potenza, C.

AU - Fabbrocini, G.

AU - Angileri, L.

AU - Bianchelli, T.

AU - Borghi, A.

AU - Buligan, C.

AU - Calabrese, G.

AU - Calzavara Pinton, P.

AU - Caroppo, F.

AU - Chello, C.

AU - Dal Bello, G.

AU - Damiani, G.

AU - Fargnoli, M. C.

AU - Ferrillo, M.

AU - Galluzzo, M.

AU - Gori, N.

AU - Gualdi, G.

AU - Hansel, K.

AU - Macchia, L.

AU - Mariano, M.

AU - Nisticò, S. P.

AU - Pertusi, G.

AU - Piras, V.

AU - Provenzano, E.

AU - Ravaioli, G. M.

AU - Ribero, S.

AU - Romanelli, M.

AU - Romita, P.

AU - Tolino, E.

AU - Trifirò, C.

PY - 2020

Y1 - 2020

N2 - Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

AB - Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

KW - atopic dermatitis

KW - dupilumab

KW - atopic dermatitis

KW - dupilumab

UR - http://hdl.handle.net/10807/168646

U2 - 10.1111/jdv.17094

DO - 10.1111/jdv.17094

M3 - Article

SP - N/A-N/A

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

ER -

Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this